Abilify drives modest pharma growth at Otsuka
This article was originally published in Scrip
Net pharmaceutical sales at Otsuka Pharmaceutical rose by 2% to ¥545.3 billion ($6.55 billion) in the nine months to 31 December, accounting for two-thirds of the business of parent Otsuka Holdings and driven by US growth for the atypical antipsychotic Abilify (aripiprazole).
You may also be interested in...
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.